Skip to content
Subscriber Only
Politics
Prognosis

J&J Pause Risks Hesitancy Even as U.S. Sees Ample Shots

  • Moderna, Pfizer shots make up the bulk of U.S. vaccine supply
  • Pfizer CEO says it can deliver 10% more doses by end of May
Video player cover image
WATCH: The White House says there’s still enough vaccine to continue giving shots at their current pace.Source: Bloomberg)
Updated on

Johnson & Johnson’s Covid-19 vaccine represents only a sliver of the current U.S. supply, but pausing its use could present new hurdles for an immunization campaign that needs to overcome wider vaccine hesitancy to outpace fast-spreading variants.

The sidelining of J&J, however temporary, leaves the U.S. with two other shots that already made up the bulk of its vaccination campaign -- from Pfizer Inc. and Moderna Inc. Vaccines from those two companies account for 95% of the shots allocated in the U.S. this week.